Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Jul 28, 2016 7:33pm
129 Views
Post# 25093897

RE:RE:NEW NR RE YEAR END DISCLOSURES

RE:RE:NEW NR RE YEAR END DISCLOSURESGV, I was under the impression that with the Hepalink deal that RVX would have enough funds to complete the BETonMACE trial. Of course that goes back a long way and things change.

I'm not too worried. Don will find the funds and also insure that the credit line will be renewed. I really don't believe that NGN, Eastern and/or Hepalink want to disrupt BoM because it is completely to their advantage to keep this moving.

I certainly hope there are no malicious players in this game but when things start to move greed takes over. That is why I like the fact that there are at least 3 big players involved. Then add to that the next regional deal (which Don seemed very confident about)!

It would certainly help if Don makes a definitive statement on these issues but he has 15 years of success under his belt (not that I condone his flippant remarks and attitudes).

I do not expect anything from the AGM.

In the early days I veiwed RVX as a very simple rvx-208 company. But over the years IMHO Don, with the Hepalink deal among all of the previous financings I staretd to realize this organization is far more complex scientifically and from a business strategy point of view.

As I have realized and stated in past posts both Zenith and Resverlogix are really scientific platforms and potential production companies for many indications and the machinery to address needs from other development companies plus the potential for downstream revenue from specific molecules like rvx-208 (apabetalone) and zen3694 in the mCRPC trial.

I'm still pumped.
Cheers
Toinv
Bullboard Posts